WO2005046586A8 - M3 muscarinic acetylcholine receptor antagonists - Google Patents

M3 muscarinic acetylcholine receptor antagonists

Info

Publication number
WO2005046586A8
WO2005046586A8 PCT/US2004/036663 US2004036663W WO2005046586A8 WO 2005046586 A8 WO2005046586 A8 WO 2005046586A8 US 2004036663 W US2004036663 W US 2004036663W WO 2005046586 A8 WO2005046586 A8 WO 2005046586A8
Authority
WO
WIPO (PCT)
Prior art keywords
receptor antagonists
acetylcholine receptor
muscarinic acetylcholine
muscarinic
methods
Prior art date
Application number
PCT/US2004/036663
Other languages
French (fr)
Other versions
WO2005046586A3 (en
WO2005046586A2 (en
Inventor
Zehong Wan
Hongxing Yan
Michael R Palovich
Dramane I Laine
Original Assignee
Glaxo Group Ltd
Zehong Wan
Hongxing Yan
Michael R Palovich
Dramane I Laine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP04810294A priority Critical patent/EP1682142B1/en
Application filed by Glaxo Group Ltd, Zehong Wan, Hongxing Yan, Michael R Palovich, Dramane I Laine filed Critical Glaxo Group Ltd
Priority to DK04810294.1T priority patent/DK1682142T3/en
Priority to ES04810294T priority patent/ES2390458T3/en
Priority to PL04810294T priority patent/PL1682142T3/en
Priority to US10/577,834 priority patent/US7439255B2/en
Priority to JP2006539633A priority patent/JP4846592B2/en
Priority to SI200431928T priority patent/SI1682142T1/en
Publication of WO2005046586A2 publication Critical patent/WO2005046586A2/en
Publication of WO2005046586A3 publication Critical patent/WO2005046586A3/en
Publication of WO2005046586A8 publication Critical patent/WO2005046586A8/en
Priority to US11/774,885 priority patent/US7563803B2/en
Priority to US12/504,194 priority patent/US7906531B2/en
Priority to HRP20120775TT priority patent/HRP20120775T1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D451/00Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Muscarinic Acetylcholine receptor antagonists and methods of using them are provided.
PCT/US2004/036663 2003-11-04 2004-11-04 M3 muscarinic acetylcholine receptor antagonists WO2005046586A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
JP2006539633A JP4846592B2 (en) 2003-11-04 2004-11-04 M3 muscarinic acetylcholine receptor antagonist
DK04810294.1T DK1682142T3 (en) 2003-11-04 2004-11-04 M3-muscarinic acetylcholine receptor antagonists
ES04810294T ES2390458T3 (en) 2003-11-04 2004-11-04 M3 muscarinic acetylcholine receptor antagonists
PL04810294T PL1682142T3 (en) 2003-11-04 2004-11-04 M3 muscarinic acetylcholine receptor antagonists
US10/577,834 US7439255B2 (en) 2003-11-04 2004-11-04 Muscarinic acetylcholine receptor antagonists
EP04810294A EP1682142B1 (en) 2003-11-04 2004-11-04 M3 muscarinic acetylcholine receptor antagonists
SI200431928T SI1682142T1 (en) 2003-11-04 2004-11-04 M3 muscarinic acetylcholine receptor antagonists
US11/774,885 US7563803B2 (en) 2003-11-04 2007-07-09 M3 muscarinic acetylcholine receptor antagonists
US12/504,194 US7906531B2 (en) 2003-11-04 2009-07-16 M3 muscarinic acetylcholine receptor antagonists
HRP20120775TT HRP20120775T1 (en) 2003-11-04 2012-10-01 M3 muscarinic acetylcholine receptor antagonists

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51724303P 2003-11-04 2003-11-04
US60/517,243 2003-11-04

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10/577,834 A-371-Of-International US7439255B2 (en) 2003-11-04 2004-11-04 Muscarinic acetylcholine receptor antagonists
US11/774,885 Continuation US7563803B2 (en) 2003-11-04 2007-07-09 M3 muscarinic acetylcholine receptor antagonists

Publications (3)

Publication Number Publication Date
WO2005046586A2 WO2005046586A2 (en) 2005-05-26
WO2005046586A3 WO2005046586A3 (en) 2005-07-28
WO2005046586A8 true WO2005046586A8 (en) 2005-09-01

Family

ID=34590145

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/036663 WO2005046586A2 (en) 2003-11-04 2004-11-04 M3 muscarinic acetylcholine receptor antagonists

Country Status (15)

Country Link
US (3) US7439255B2 (en)
EP (1) EP1682142B1 (en)
JP (1) JP4846592B2 (en)
AR (1) AR046225A1 (en)
CY (1) CY1113295T1 (en)
DK (1) DK1682142T3 (en)
ES (1) ES2390458T3 (en)
HR (1) HRP20120775T1 (en)
PE (1) PE20050489A1 (en)
PL (1) PL1682142T3 (en)
PT (1) PT1682142E (en)
SI (1) SI1682142T1 (en)
TW (1) TW200524577A (en)
UY (1) UY28598A1 (en)
WO (1) WO2005046586A2 (en)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200519108A (en) * 2003-07-17 2005-06-16 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
CN101230061A (en) * 2003-10-14 2008-07-30 葛兰素集团有限公司 Muscarinic acetycholine receptor antagonists
JP2007509061A (en) * 2003-10-17 2007-04-12 グラクソ グループ リミテッド Muscarinic acetylcholine receptor antagonist
AR046225A1 (en) * 2003-11-04 2005-11-30 Glaxo Group Ltd COMPOSITE OF 8-AZONIABICICLO (3.2.1) OCTOBER, PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DISEASES MEDIATED BY MUSCARINIC ACETILCOLINE RECEPTORS THAT UNDERSTAND IT AND USE OF THE COMPOUND TO PREPARE SUCH COMPOSITION
EP1725236A4 (en) * 2004-03-11 2009-05-13 Glaxo Group Ltd Novel m3 muscarinic acetylcholine receptor antagonists
WO2005095407A1 (en) * 2004-03-17 2005-10-13 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
UY28871A1 (en) 2004-04-27 2005-11-30 Glaxo Group Ltd ANTAGONISTS OF THE MUSCARINIC ACETILCOLINE RECEIVER
JP2007537261A (en) * 2004-05-13 2007-12-20 グラクソ グループ リミテッド Muscarinic acetylcholine receptor antagonist
US7932247B2 (en) * 2004-11-15 2011-04-26 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
EP1937267A4 (en) * 2005-08-02 2009-08-26 Glaxo Group Ltd M3 muscarinic acetylcholine receptor antagonists
US7767691B2 (en) * 2005-08-18 2010-08-03 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists containing an azoniabiocyclo[2.2.1] heptane ring system
JP5298008B2 (en) 2006-04-20 2013-09-25 グラクソ グループ リミテッド New compounds
GB0611587D0 (en) 2006-06-12 2006-07-19 Glaxo Group Ltd Novel compounds
EP2046787B1 (en) 2006-08-01 2011-04-06 Glaxo Group Limited Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors
AR065804A1 (en) 2007-03-23 2009-07-01 Smithkline Beecham Corp COMPOSITE OF INDOL CARBOXAMIDE, PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS IT AND USE OF THIS COMPOUND TO PREPARE A MEDICINAL PRODUCT
AR070562A1 (en) 2008-02-06 2010-04-21 Glaxo Group Ltd DUAL PHARMACOPHORS - PDE4 MUSCARINIC ANTAGONISTS
UY31636A1 (en) 2008-02-06 2009-08-03 DUE PHARMACOPHORES-MUSCARINIC ANTAGONISTS OF PDE4
AR070564A1 (en) 2008-02-06 2010-04-21 Glaxo Group Ltd DERIVATIVES OF 1H-PIRAZOLO [3,4-B] PIRIDIN-5-ILO, PDE4 PHOSPHODIESTERASE INHIBITORS AND ACETILCOLINE MUSCARINIC RECEPTORS (MACHR) ANTAGONISTS, USEFUL IN THE TREATMENT AND / OR PROFILAXES AND PHYSPHOSITIZES, PHYSPHOSYSTEMS, AND PHARMOSES THAT UNDERSTAND THEM
US8163743B2 (en) 2008-06-05 2012-04-24 GlaxoGroupLimited 4-carboxamide indazole derivatives useful as inhibitors of PI3-kinases
WO2009147190A1 (en) 2008-06-05 2009-12-10 Glaxo Group Limited Novel compounds
WO2010094643A1 (en) 2009-02-17 2010-08-26 Glaxo Group Limited Quinoline derivatives and their uses for rhinitis and urticaria
WO2010102958A1 (en) 2009-03-09 2010-09-16 Glaxo Group Limited 4-oxadiazol-2 -yl- indazoles as inhibitors of p13 kinases
EP2406249A1 (en) 2009-03-10 2012-01-18 Glaxo Group Limited Indole derivatives as ikk2 inhibitors
WO2010106016A1 (en) 2009-03-17 2010-09-23 Glaxo Group Limited Pyrimidine derivatives used as itk inhibitors
CN102459253B (en) 2009-04-30 2015-03-25 葛兰素集团有限公司 Oxazole substituted indazoles as pi3-kinase inhibitors
US20100330607A1 (en) * 2009-06-24 2010-12-30 Photoswitch Biosciences, Inc. Photoswitch-enabled ion channel assay system
US20120245171A1 (en) 2009-12-03 2012-09-27 Glaxo Group Limited Benzpyrazole derivatives as inhibitors of pi3 kinases
WO2011067364A1 (en) 2009-12-03 2011-06-09 Glaxo Group Limited Novel compounds
WO2011067366A1 (en) 2009-12-03 2011-06-09 Glaxo Group Limited Indazole derivatives as pi 3 - kinase inhibitors
WO2011110575A1 (en) 2010-03-11 2011-09-15 Glaxo Group Limited Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases
JP5965402B2 (en) 2010-09-08 2016-08-03 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited N- [5- [4- (5-{[(2R, 6S) -2,6-dimethyl-4-morpholinyl] methyl} -1,3-oxazol-2-yl) -1H-indazol-6-yl ] -2- (Methyloxy) -3-pyridinyl] methanesulfonamide polymorphs and salts
WO2012035055A1 (en) 2010-09-17 2012-03-22 Glaxo Group Limited Novel compounds
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
US20160263109A1 (en) 2013-10-17 2016-09-15 Glaxosmithkline Intellectual Property Development Limited P13k inhibitor for treatment of respiratory disease
CA2923995A1 (en) 2013-10-17 2015-04-23 Glaxosmithkline Intellectual Property Development Limited Pi3k inhibitor for treatment of respiratory disease
JP2017515840A (en) 2014-05-12 2017-06-15 グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited Pharmaceutical composition comprising tanilyxin for treating infectious diseases
GB201602527D0 (en) 2016-02-12 2016-03-30 Glaxosmithkline Ip Dev Ltd Chemical compounds
US20190161480A1 (en) 2016-08-08 2019-05-30 Glaxosmithkline Intellectual Property Development Limited Chemical Compounds
GB201706102D0 (en) 2017-04-18 2017-05-31 Glaxosmithkline Ip Dev Ltd Chemical compounds
GB201712081D0 (en) 2017-07-27 2017-09-13 Glaxosmithkline Ip Dev Ltd Chemical compounds
WO2021191875A1 (en) 2020-03-26 2021-09-30 Glaxosmithkline Intellectual Property Development Limited Cathepsin inhibitors for preventing or treating viral infections

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2800481A (en) * 1955-07-01 1957-07-23 Smith Kline French Lab Tertiary alcohol derivatives of 8-alkylnortropanes and the acid and quaternary ammonium salts thereof
US2800478A (en) * 1955-07-01 1957-07-23 Smith Kline French Lab 3-substituted-8-alkylnortropanes and the acid and quaternary ammonium salts thereof
AT298118B (en) * 1967-06-08 1972-04-25 Siemens Ag Method for converting voltages into digital values and device for carrying out the method
GB1242211A (en) 1967-08-08 1971-08-11 Fisons Pharmaceuticals Ltd Pharmaceutical composition
GB1230087A (en) 1967-08-17 1971-04-28
GB1381872A (en) 1971-06-22 1975-01-29 Fisons Ltd Pharmaceutical compositions for inhalation
GB2064336B (en) 1979-12-06 1984-03-14 Glaxo Group Ltd Device for dispensing medicaments
CY1492A (en) 1981-07-08 1990-02-16 Draco Ab Powder inhalator
GB2169265B (en) 1982-10-08 1987-08-12 Glaxo Group Ltd Pack for medicament
AU570013B2 (en) 1982-10-08 1988-03-03 Glaxo Group Limited Medicament inhaler
DK163640C (en) 1985-07-30 1992-08-17 Glaxo Group Ltd DEVICE FOR ADMINISTRATING MEDICINES
IT1204826B (en) 1986-03-04 1989-03-10 Chiesi Farma Spa INHALATION PHARMACEUTICAL COMPOSITIONS
CA1328106C (en) * 1986-03-17 1994-03-29 Nicholas S. Bodor Anticholinergic compounds, pharmaceutical compositions and method of treatment
GB9000304D0 (en) * 1990-01-06 1990-03-07 Pfizer Ltd Muscarinic receptor antagonists
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
JP3294961B2 (en) * 1993-12-10 2002-06-24 杏林製薬株式会社 Novel imidazole derivative and method for producing the same
US5780466A (en) * 1995-01-30 1998-07-14 Sanofi Substituted heterocyclic compounds method of preparing them and pharmaceutical compositions in which they are present
JPH0920758A (en) * 1995-07-06 1997-01-21 Kyorin Pharmaceut Co Ltd New cyclic diamine derivative and its production
EP0944626A4 (en) * 1996-12-02 2002-09-04 Univ Georgetown Tropane derivatives and method for their synthesis
US6248752B1 (en) * 1998-02-27 2001-06-19 Charles Duane Smith Azabicyclooctane compositions and methods for enhancing chemotherapy
US6262066B1 (en) * 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
ES2165768B1 (en) * 1999-07-14 2003-04-01 Almirall Prodesfarma Sa NEW DERIVATIVES OF QUINUCLIDINE AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
DE10050995A1 (en) * 2000-10-14 2002-04-18 Boehringer Ingelheim Pharma New benzylic acid azabicyclooctane ester quaternary salts useful as anticholinergic agents, especially in treatment of asthma and chronic obstructive pulmonary disease
BR0212983A (en) * 2001-10-17 2004-10-13 Ucb Sa Compound, Compound Use, and, Synthesis Intermediates
US6696462B2 (en) * 2002-01-31 2004-02-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Anticholinergics, processes for the preparation thereof, and pharmaceutical compositions
TW200410951A (en) * 2002-08-06 2004-07-01 Glaxo Group Ltd M3 muscarinic acetylcholine receptor antagonists
WO2004091482A2 (en) * 2003-04-07 2004-10-28 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
AR045913A1 (en) * 2003-07-17 2005-11-16 Glaxo Group Ltd 8-AZABICICLO OLEFINIC DERIVATIVES [3,2,1] OCTANS AS ANTAGONISTS OF ACETILCOLINE MUSCARINIC RECEPTORS
TW200519108A (en) * 2003-07-17 2005-06-16 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
PE20050711A1 (en) * 2003-07-17 2005-09-10 Glaxo Group Ltd 8-AZONIABICYCLE COMPOUNDS [3.2.1] OCTANS AS ANTAGONISTS OF MUSCARINIC ACETYLCHOLINE RECEPTORS
CN101230061A (en) * 2003-10-14 2008-07-30 葛兰素集团有限公司 Muscarinic acetycholine receptor antagonists
JP2007509061A (en) * 2003-10-17 2007-04-12 グラクソ グループ リミテッド Muscarinic acetylcholine receptor antagonist
AR046225A1 (en) * 2003-11-04 2005-11-30 Glaxo Group Ltd COMPOSITE OF 8-AZONIABICICLO (3.2.1) OCTOBER, PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DISEASES MEDIATED BY MUSCARINIC ACETILCOLINE RECEPTORS THAT UNDERSTAND IT AND USE OF THE COMPOUND TO PREPARE SUCH COMPOSITION
CA2543858C (en) * 2003-11-21 2014-04-15 Theravance, Inc. Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
UY28646A1 (en) * 2003-12-03 2005-06-30 Glaxo Group Ltd NEW ANTAGONISTS OF THE M3 ACETILCOLINE MUSCARINIC RECEPTOR
AR046784A1 (en) * 2003-12-03 2005-12-21 Glaxo Group Ltd COMPOUND OF CYCLINE AMINE PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE TO PREPARE THIS LAST
WO2005094835A1 (en) * 2004-03-17 2005-10-13 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
EP1725240A4 (en) * 2004-03-17 2009-03-25 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
WO2005095407A1 (en) * 2004-03-17 2005-10-13 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
WO2005094251A2 (en) * 2004-03-17 2005-10-13 Glaxo Group Limited M3muscarinic acetylcholine receptor antagonists
UY28871A1 (en) * 2004-04-27 2005-11-30 Glaxo Group Ltd ANTAGONISTS OF THE MUSCARINIC ACETILCOLINE RECEIVER
JP2007537261A (en) * 2004-05-13 2007-12-20 グラクソ グループ リミテッド Muscarinic acetylcholine receptor antagonist
TW200606161A (en) * 2004-05-28 2006-02-16 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
JP2008518939A (en) 2004-10-29 2008-06-05 グラクソ グループ リミテッド Muscarinic acetylcholine receptor antagonist
US20090142279A1 (en) 2004-11-15 2009-06-04 Budzik Brian W Novel m3 muscarinic acetylcholine receptor antagonists
US7932247B2 (en) 2004-11-15 2011-04-26 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
PE20060826A1 (en) 2004-12-06 2006-10-08 Smithkline Beecham Corp OLEOPHINIC DERIVATIVE OF 8-AZONIABICICLO [3.2.1] OCTANE AND THE PHARMACEUTICAL COMBINATION THAT INCLUDES IT
PE20061162A1 (en) 2004-12-06 2006-10-14 Smithkline Beecham Corp COMPOUNDS OLEFINIC DERIVATIVES OF 8-AZONIABICICLO [3.2.1] OCTANES
WO2006065788A2 (en) 2004-12-13 2006-06-22 Glaxo Group Limited Novel muscarinic acetylcholine receptor antagonists
WO2006065755A2 (en) 2004-12-13 2006-06-22 Glaxo Group Limited Quaternary ammonium salts of fused hetearomatic amines as novel muscarinic acetylcholine receptor antagonists
WO2007018514A1 (en) 2005-07-28 2007-02-15 Glaxo Group Limited Novel m3 muscarinic acetylcholine receptor antagonists
WO2007018508A1 (en) 2005-07-28 2007-02-15 Glaxo Group Limited Novel m3 muscarinic acetycholine receptor antagonists
US20080234315A1 (en) 2005-08-02 2008-09-25 Jakob Busch-Petersen M3 Muscarinic Acetylcholine Receptor Antagonists
EP1937267A4 (en) 2005-08-02 2009-08-26 Glaxo Group Ltd M3 muscarinic acetylcholine receptor antagonists
US7767691B2 (en) 2005-08-18 2010-08-03 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists containing an azoniabiocyclo[2.2.1] heptane ring system
US8617648B2 (en) * 2006-02-01 2013-12-31 Xerox Corporation Imaging members and method of treating an imaging member

Also Published As

Publication number Publication date
CY1113295T1 (en) 2016-04-13
US20070270456A1 (en) 2007-11-22
SI1682142T1 (en) 2012-10-30
WO2005046586A3 (en) 2005-07-28
PT1682142E (en) 2012-10-11
US20090275604A1 (en) 2009-11-05
US7439255B2 (en) 2008-10-21
EP1682142B1 (en) 2012-07-11
ES2390458T3 (en) 2012-11-13
UY28598A1 (en) 2005-05-31
AR046225A1 (en) 2005-11-30
PE20050489A1 (en) 2005-09-02
US20070129396A1 (en) 2007-06-07
JP4846592B2 (en) 2011-12-28
PL1682142T3 (en) 2012-11-30
US7563803B2 (en) 2009-07-21
HRP20120775T1 (en) 2012-10-31
JP2007510731A (en) 2007-04-26
EP1682142A2 (en) 2006-07-26
US7906531B2 (en) 2011-03-15
WO2005046586A2 (en) 2005-05-26
DK1682142T3 (en) 2012-10-15
EP1682142A4 (en) 2009-11-25
TW200524577A (en) 2005-08-01

Similar Documents

Publication Publication Date Title
WO2005046586A8 (en) M3 muscarinic acetylcholine receptor antagonists
WO2004012684A3 (en) M3muscarinic acetylcholine receptor antagonists
WO2006055553A3 (en) Novel m3 muscarinic acetylcholine receptor antagonists
WO2005104745A3 (en) Muscarinic acetylcholine receptor antagonists
WO2006055503A3 (en) Novel m3 muscarinic acetylcholine receptor antagonists
WO2006065788A3 (en) Novel muscarinic acetylcholine receptor antagonists
WO2005067537A3 (en) Muscarinic acetylcholine receptor antagonists
MY143366A (en) Muscarinic acetylcholine receptor antagonists
WO2005055941A3 (en) Novel m3 muscarinic acetylcholine receptor antagonists
TW200600093A (en) M3 muscarinic acetylcholine receptor antagonists
WO2006050239A3 (en) Muscarinic acetylcholine receptor antagonists
WO2005112644A3 (en) Muscarinic acetylcholine receptor antagonists
WO2005055940A3 (en) Novel m3 muscarinic acetylcholine receptor antagonists
WO2006062931A3 (en) Medical combinations
WO2007022351A3 (en) Muscarinic acetylcholine receptor antagonists
WO2007016639A3 (en) M3 muscarinic acetylcholine receptor antagonists
WO2007016650A3 (en) M3 muscarinic acetylcholine receptor antagonists
WO2006062883A3 (en) Medical combinations
WO2006005057A3 (en) Muscarinic acetylcholine receptor antagonists
TW200600500A (en) M3 muscarinic acetylcholine receptor antagonists
TW200606161A (en) Muscarinic acetylcholine receptor antagonists
WO2006017768A3 (en) Muscarinic acetylcholine receptor antagonists
EP1725236A4 (en) Novel m3 muscarinic acetylcholine receptor antagonists
WO2005009362A3 (en) Muscarinic acetylcholine receptor antagonists
MXPA06000662A (en) Muscarinic acetylcholine receptor antagonists.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 21/2005 UNDER (72, 75) DELETE "LEE, DENNIS; STAVENGER, ROBERT, A.; GOODMAN, KRISTA, B.; HILFIKER; MARK, A.; CUI, HAIFENG; VIET, ANDREW, W.; MARINO, JOSEPH, P."

WWE Wipo information: entry into national phase

Ref document number: 2004810294

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007129396

Country of ref document: US

Ref document number: 10577834

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2006539633

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2004810294

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 10577834

Country of ref document: US